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Human epidermal growth factor receptor 2 (HER2) status is one of the
major tumor characteristics in breast cancer to guide therapy. Anti-
HER2 treatment has clear survival advantages in HER2-positive breast
carcinoma patients. Heterogeneity in HER2 expression between
primary tumor and metastasis has repeatedly been described, result-
ing in the need to reassess HER2 status during the disease course. To
avoid repeated biopsy with potential bias due to tumor heterogeneity,
Nanobodies directed against HER2 have been developed as probes
for molecular imaging. Nanobodies, which are derived from unique
heavy-chain-only antibodies, are the smallest antigen-binding antibody
fragments and have ideal characteristics for PET imaging. The primary
aims were assessment of safety, biodistribution, and dosimetry. The
secondary aim was to investigate tumor-targeting potential.Methods:
In total, 20 women with primary or metastatic breast carcinoma (score
of 21 or 31 on HER2 immunohistochemical assessment) were in-
cluded. Anti-HER2-Nanobody was labeled with 68Ga via a NOTA de-
rivative. Administered activities were 53–174 MBq (average, 107 MBq).
PET/CT scans for dosimetry assessment were obtained at 10, 60, and
90 min after administration. Physical evaluation and blood analysis
were performed for safety evaluation. Biodistribution was analyzed
for 11 organs using MIM software; dosimetry was assessed using
OLINDA/EXM. Tumor-targeting potential was assessed in primary
and metastatic lesions. Results: No adverse reactions occurred.
A fast blood clearance was observed, with only 10% of injected
activity remaining in the blood at 1 h after injection. Uptake was
seen mainly in the kidneys, liver, and intestines. The effective dose
was 0.043 mSv/MBq, resulting in an average of 4.6 mSv per pa-
tient. The critical organ was the urinary bladder wall, with a dose of
0.406 mGy/MBq. In patients with metastatic disease, tracer accumu-
lation well above the background level was demonstrated in most
identified sites of disease. Primary lesions were more variable in
tracer accumulation.Conclusion: 68Ga-HER2-Nanobody PET/CT is a
safe procedure with a radiation dose comparable to other routinely
used PET tracers. Its biodistribution is favorable, with the highest
uptake in the kidneys, liver, and intestines but very low background
levels in all other organs that typically house primary breast carci-
noma or tumor metastasis. Tracer accumulation in HER2-positive
metastases is high, compared with normal surrounding tissues, and
warrants further assessment in a phase II trial.
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One in 8 women develops breast cancer, and it remains the
second leading cause of cancer death in women. Identification of
cancer subtypes based on biologic markers has led to the introduc-
tion of targeted therapies, with improved survival and morbidity.
Besides hormone receptor expression, human epidermal growth fac-
tor receptor 2 (HER2) is used for breast cancer classification. Breast
cancers with HER2 overexpression in primary or metastatic sites
will benefit from HER2-targeted therapies such as the monoclonal
antibody trastuzumab, resulting in a clear survival advantage (1).
Because only 20% of breast cancers overexpress HER2, the
decision to start HER2-targeted therapy is based on immunohisto-
chemical assessment or demonstrated gene amplification (e.g., fluo-
rescence in situ hybridization) on tumor tissue biopsy, usually
obtained at initial diagnosis at the primary site. Only patients with
strong expression of the protein (31 on immunohistochemical as-
sessment) or with strong amplification of the HER2 gene (fluores-
cence in situ hybridization–positive) are selected for HER2-targeted
therapy, as these patients gain the greatest clinical benefit from
trastuzumab treatment (1). In most therapeutic protocols, HER2-
targeted therapy is given in addition to classic chemotherapy (e.g.,
paclitaxel, docetaxel). Recently, this approach was optimized by
linking a chemotoxin to the antibody, thereby specifically targeting it
to HER2-positive tumor cells. This compound, named trastuzumab
emtansine, showed improved efficacy while reducing toxicity (2).
Studies have shown a HER2 testing discrepancy between local
and large reference laboratories, resulting in 14%–16% false-positive
and 4% false-negative results (3,4). Such misclassification gives rise
to unnecessary toxicity and cost for the former while denying a
potentially efficacious therapy for the latter. Recently, several in-
dependent studies reported a significant discordance in HER2 ex-
pression between primary breast carcinoma and metastases ranging
between 6% and 34%, as well as heterogeneity between metastases
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(5–10). Because of this discordance, the European guidelines now
recommend that a biopsy of a metastatic lesion be obtained to
reassess biologic markers (11). With the increasing use of trastuzu-
mab emtansine, which affects only HER2-overexpressing cancer
cells, the importance of correct HER2 assessment becomes even
more important.
We here introduce the use of Nanobodies (trade name of Ablynx)
directed against HER2 as probes for molecular imaging in breast
carcinoma patients. Nanobodies are the smallest antigen-binding
domains derived from unique heavy-chain-only antibodies that are
naturally present in camelids. Nanobodies have proven to be ideal
probes for SPECT and PET imaging in rodents, with high targeting
potential and fast blood clearance (12,13). The anti-HER2-Nanobody
2Rs15 d was selected and optimized as the lead compound for clinical
translation (14,15). In this paper we report on the safety, biodistribu-
tion, dosimetry, and tumor-targeting potential of the 68Ga-anti-HER2-
Nanobody (68Ga-HER2-Nanobody) in breast carcinoma patients.
MATERIALS AND METHODS
This was an open-label phase I study in HER2-expressing breast
carcinoma patients (n 5 20). The supplemental data (available at http://
jnm.snmjournals.org) provide details on approvals, patient selection,
safety assessment, conjugation of p-SCN-Bn-NOTA chelator to anti-
HER2 Nanobody, synthesis of 68Ga-HER2-Nanobody, the PET/CT pro-
tocol, image processing and analysis, blood and urine analysis, detection
of antidrug antibodies, region-of-interest definition, dosimetry, uptake in
tumor lesions, and statistical analysis.
Three subgroups, receiving, respectively, 0.01 mg (patients 1–7),
0.1 mg (patients 8–15), and 1.0 mg (patients 16–20) of NOTA-anti-
HER2-Nanobody were evaluated for a difference in normal biodistri-
bution, to investigate a potential decrease in nonspecific binding in
nontarget organs with increasing mass of tracer. The activity admin-
istered was similar for the different patient groups and ranged from 53
to 174 MBq.
RESULTS
Patient Characteristics
Between April 2012 and July 2014, 20 patients completed the
study protocol. The patients received on average 107 6 37 MBq
(range, 53–174 MBq) of 68Ga-HER2-Nanobody. Patient and study
drug characteristics are summarized in Table 1.
Safety Assessment
After the administration of 68Ga-HER2-Nanobody, no symptoms
or signs of toxicity were reported. Clinical laboratory testing of blood,
taken before and 120 min after injection, showed no significant
changes that could be related to the study drug. Antidrug antibody
was not detected in serum samples of 20 patients taken before and
3 mo after administration (Supplemental Fig. 1).
Pharmacokinetics and Biodistribution
Figure 1 shows images of representative patients for each sub-
group. No obvious differences in biodistribution were noted between
different subgroups by visual comparison.
Blood-pool activity was visible only at 10 min after injection, with
weak delineation of the heart and large blood vessels. Uptake was seen
mainly in the kidneys, liver, and intestines. This uptake pattern was
already present on the 10-min images and decreased over time. Weak
uptake was seen in glandular tissues such as the thyroid, pituitary,
salivary glands, lacrimal glands, and sweat glands.
The uptake of 68Ga-HER2-Nanobody in individual organs is pre-
sented in Figure 2 and Supplemental Table 1. Blood-pool activity is
presented in Figure 3. A fast blood clearance was seen, with only
10% of injected activity remaining in the blood at 1 h after injection.
Blood half-lives were calculated at 2.9 min (early phase) and
25.5 min (late phase). Plasma curves were identical to blood curves,
indicating that the tracer was not associated with blood cells. After
injection, no metabolites were detected for up to 10 min in blood or
up to 2 h in urine.
All images showed uptake in kidneys and excretion of the tracer
into the urine. Although liver and intestine uptake was visible, there
were no signs of hepatobiliary excretion, such as an accumulation in
the gallbladder or duodenum. At 1 h after injection, 50% of the
tracer had been eliminated from the body, resulting in an estimated
biologic half-life of 1 h (Supplemental Fig. 2).
Effect of Injected Mass on Liver Uptake
On the basis of the preclinical results, the injected mass of the
compound was expected to have an effect on nonspecific binding.
Therefore, liver uptake was assessed in the 3 subgroups receiving
different amounts of Nanobody. Overall, liver uptake was quite
variable among patients. There was a trend toward lower liver uptake
at 90 min after injection in the 1.0-mg group, with an average uptake
of 5.5% injected activity compared with 9.0% and 9.5% injected
activity for 0.1 and 0.01 mg, respectively, but with overlapping 95%
confidence intervals (3.3–7.6, 5.7–12.3, and 7.4–11.5, respectively).
One-way ANOVA indicated no significant difference (F2,15 5 3.60,
P 5 0.053).
Dosimetry
Table 2 summarizes the individual organ doses and individual
effective dose results for all subjects with normal liver and renal
function. The urinary bladder wall showed the highest organ dose
(0.406 mGy/MBq), followed by the kidneys (0.216 mGy/MBq),
liver (0.0778 mGy/MBq), lower large intestine wall (0.0759 mGy/
MBq), and upper large intestine wall (0.0619 mGy/MBq).
Uptake in Tumor Lesions
Uptake in tumor lesions could be evaluated in 19 patients, 9 of
whom had only a primary lesion; 6, both a primary lesion and
local or distant metastases; and 4, only local or distant metastases
(Table 1).
Uptake in Primary Lesions. Tracer uptake was visible for 13 of 15
primary tumors, with SUVmean ranging from 0.7 to 11.8 (Table 1).
Representative images showing 68Ga-HER2-Nanobody uptake in
primary lesions are presented in Figure 4.
Uptake in Local and Distant Metastases. All patients with
metastatic lesions showed clear tracer accumulation in at least 1
lesion, with SUVmean ranging from 3.1 to 6.0. Figure 5 shows im-
ages of patients 18 and 20, with metastases in thoracic lymph nodes
and the pelvis, respectively. Supplemental Video 1 shows maximum-
intensity-projection PET images of patient 14 at 90 min after in-
jection. This patient presented with a primary mammary carcinoma
on the right side and an ipsilateral invaded axillary lymph node.
Heterogeneous Uptake Pattern. In patient 8, a heterogeneous
uptake pattern was observed in the primary tumor (Supplemental Fig.
3A). The uptake pattern did not match the 18F-FDG uptake pattern,
indicating that it was not caused by necrotic tumor areas. The patient
presented with diffuse metastases, of which some but not all showed
uptake (SUVmean range, 1.0–5.6; Supplemental Figs. 3B and 3C).
DISCUSSION
This first-in-human application of a radiolabeled Nanobody demon-
strates that the procedure is safe and that tracer administration causes
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no observable adverse reactions. The 68Ga-HER2-Nanobody tracer
showed a favorable biodistribution, with the highest uptake in the
kidneys, liver, and intestines but very low background levels in
all other organs that typically harbor primary breast carcinoma or
tumor metastasis. Antidrug antibody measurements showed that
no preexisting or tracer-induced antibodies against the Nanobody
could be detected.
Rapid tracer clearance from the blood allows imaging at early time
points (60–90 min after injection) without the risk of false-positive
signal due to blood-pool activity. Tracer elimination occurs through
the renal system, with high accumulation in the kidneys, similar to
patterns described for other labeled peptides and small proteins (16–
18) and as expected from Nanobody uptake patterns in rodents (19).
Organs with substantial uptake are the liver and intestines. Although
the literature describes a low expression of HER2 in the liver, the
uptake most likely is of a nonspecific nature, given the high and
probably supraphysiologic uptake values (20). Liver uptake may
obscure liver metastases, but given the absence of liver metasta-
ses in this patient group, the question remains unanswered. On
the basis of preclinical observations, increasing amounts of protein
up to 1 mg were administered to 3 different patient subgroups in an
attempt to decrease nonspecific binding, but no significant effect
was observed.
Because liver uptake continues to decrease between 60 and 90 min
after injection, the latter is proposed as the best time point to obtain
images with an optimal signal-to-noise ratio. Later time points were
not assessed in this study because of the short half-life of 68Ga.
Whole-body imaging revealed weak tracer uptake in glandular
tissues such as the salivary glands, pituitary, lacrimal glands, and
axillary sweat glands. This pattern was also observed with 68Ga-
and 111In-labeled anti-HER2-Affibody (21). The origin of this
uptake remains to be determined but may be related to low levels
of HER2 expression or chelator-mediated trapping mechanisms.
Clinical testing of 18F-anti-HER2-Nanobody may provide more
insight (22). It is, however, noteworthy that prostate-specific
membrane antigen tracers show even more pronounced glandular
uptake for both 68Ga- and 18F-labeled compounds, suggesting a
specific uptake mechanism (17,23).
TABLE 1
Patient Characteristics
Group
Patient
no.
Age
(y)
IA
(MBq)
Tumor
type ER/PR
HER2
IHC
HER2 FISH
Range of SUVmean of lesions
Positivity Ratio Copies/cell
Primary
tumor
Local
ADP
Distant M1
(type)
0.01 mg 1 43 77 IDC 1/1 21 1 2.2 6.2 ISR* A A
2 60 66 IDC 1/1 31 1 .2 Macroclusters CR A 3.1 (bone)
3 68 53 IDC 1/1 31 1 12.2 20.0 3.2 A A
4 53 76 IDC 1/1 21 − 1.3 3.7 2.2 A A
5 74 84 IDC 1/1 21 − 1.3 3.8 2.3 A A
6 34 83 IMeC 1/− 31 1 2.8 8.0 0.9 A A
7 34 80 IDC 1/1 21 − 1.0 1.4 2.0 A A
0.1 mg 8 67 92 IDC 1/1 21 − 1.4 3.4 5.0 3.2–4.3 1.0–5.6 (bone)
9 57 111 IDC 1/1 31 1 1.3 6.1 2.3 A A
10 61 100 IDC 1/− 31 1 9.4 15.0 SR SR 4.1–5.7 (bone)
11 65 90 IDC 1/1 31 1 2.3 5.1 2.9 6.3 A
12 46 82 IDC 1/1 31 1 8.1 15.6 1.4 A A
13 32 153 IDC −/− 21 1 9.4 17.4 3.2 1.7 A
14 53 103 IDC −/− 31 1 4.7 9.2 11.8 13.0 A
15 78 148 IDC 1/1 21 − 1.0 2.1 4.9 A A
1.0 mg 16 76 96 ILC 1/1 21 − 1.0 1.7 SR SR 2.2–3.9 (bone)
17 74 138 IDC −/− 21 − 1.2 4.3 1.8 A A
18 62 167 IDC 1/− 21 1 2.6 4.5 SR SR 3.5–6.0 (ADP
mediastinum)
19 62 174 IMiC 1/1 31 1 2.8 8.0 4.4 5.1–5.9 3.6–3.9 (bone)
20 48 170 IDC 1/1 31 1 7.8 15.6 0.7† A 4.7–5.4 (bone)†
*Patient was scanned after incomplete surgical removal but additional surgical resection could not demonstrate remaining tumor
cells.
†After 4 cycles of epirubicin cyclophosphamide.
FISH 5 fluorescence in situ hybridization; IA 5 injected activity; ER 5 estrogen receptor; PR 5 progesterone receptor; IHC 5
immunohistochemical assessment; ADP 5 adenopathy; IDC 5 invasive ductal carcinoma; ISR 5 incomplete surgical removal; A 5
absent; CR 5 complete response on CT; IMeC 5 invasive medullary carcinoma; SR 5 surgically removed; ILC 5 invasive lobular
carcinoma; IMiC 5 invasive mixed carcinoma.
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The urinary bladder wall received the highest organ dose,
0.406 mGy/MBq, which at the highest injected activity of 185 MBq
is well below 100 mGy, thereby excluding potential deterministic
effects. The average radiation burden was 0.04 mSv/MBq, which
resulted in an average effective dose of 4.6 mSv for the 18 patients
in this study. Maintaining a maximum activity of 185 MBq for
future imaging studies, the highest effective dose would be 7.9 mSv.
These values are acceptable for a diagnostic procedure and in line
with other 68Ga and 18F PET radiotracers (16,24).
Although not the primary objective of this phase I study, tumor
uptake was evaluated in these breast carcinoma patients, both in
primary lesions and in metastases.
Uptake in primary lesions showed a wide range of 0.7–11.8,
possibly because of the heterogeneous composition of primary
lesions, with tumor cells infiltrating normal breast tissue. More-
over, patient 20, with an SUVmean of 0.7, had received 4 cycles of
chemotherapy, which could explain the negative result. Additionally,
carcinoma in situ can coincide with infiltrating carcinoma, which
can mimic uptake in the invasive carcinoma, since these carcinomas
in situ can also overexpress HER2 while not correlating with HER2
expression in metastatic lesions. 68Ga-HER2-Nanobody PET/CT
may therefore not be ideal for assessing HER2 expression in primary
breast carcinoma lesions.
FIGURE 2. Uptake, expressed in percentage injected activity (IA), in
different organs at 10, 60, and 90 min after injection (n 5 18).
FIGURE 3. Time–activity curve of total blood activity, expressed in
percentage injected activity (IA). Data are mean and SD of 12 patients.
FIGURE 1. Representative maximum-intensity-projection images at 10,
60, and 90 min after injection of 68Ga-HER2-Nanobody for different mass
subgroups. (A) Patient 4, injected with 0.01 mg of 68Ga-HER2-Nanobody.
(B) Patient 12, injected with 0.1 mg. (C) Patient 17, injected with 1.0 mg.
30 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 57 • No. 1 • January 2016
by Christian Vanhove on January 6, 2016. For personal use only. jnm.snmjournals.org Downloaded from 
In patients with metastatic disease, however, distinct uptake was
seen in most metastases. In two of these patients, the tumor was
classified as HER2-negative, on the basis of a score of 21 on immu-
nohistochemical assessment and fluorescence in situ hybridization–
negative results in the primary tumor. The increased tracer uptake
may be related to intermediate HER2 expression (score of 21 on
immunohistochemical assessment) or to discordance in HER2 ex-
pression between the primary lesion and the metastasis, as has been
described in the literature for 14%–30% of cases (7,10). Given the
absence of direct histopathologic correlation in this phase I study, a
final conclusion based on the current results
cannot be made. Sensitivity and specificity
for the determination of HER2 status will
be answered only through larger, prospec-
tive, and more clinically focused imaging
trials.
Other research groups have developed
PET/CT imaging strategies in parallel
using the full therapeutic antibody trastu-
zumab labeled with 89Zr or 64Cu (25,26).
This approach, however, has the disadvan-
tage of slow blood clearance, resulting in a
late imaging time point of 1–2 d (64Cu) or
4–5 d (89Zr) after tracer injection, a long
scanning time of up to 1 h, and a high
radiation burden of 12 mSv (64Cu) or
18 mSv (89Zr) for the patient (25,27,28).
To overcome these disadvantages, antibody
fragments derived from trastuzumab, such
as F(ab9)2, have been developed and la-
beled with shorter-lived isotopes. 68Ga-
DOTA-F(ab9)2-trastuzumab showed minimal
TABLE 2
Organ Doses and Effective Dose
Organ dose (mGy/MBq) Effective
dose
(mSv/MBq)Patient no. UB wall Kidneys Liver LLI wall ULI wall Thyroid
1 0.406 0.191 0.0515 0.0843 0.0606 0.0233 0.0425
3 0.406 0.161 0.114 0.0757 0.0679 0.0326 0.0458
4 0.405 0.219 0.0788 0.0295 0.0787 0.0257 0.0371
5 0.407 0.181 0.116 0.0962 0.0566 0.0093 0.0472
6 0.406 0.297 0.0957 0.0798 0.0535 0.0282 0.0453
7 0.405 0.259 0.0788 0.0423 0.0840 0.0020 0.0371
8 0.405 0.141 0.114 0.0788 0.0715 0.0137 0.0433
9 0.406 0.273 0.0740 0.0686 0.0675 0.0200 0.0421
10 0.406 0.229 0.0922 0.0626 0.0991 0.0035 0.0425
12 0.407 0.220 0.0594 0.0816 0.0772 0.0327 0.0435
13 0.406 0.225 0.113 0.0632 0.0812 0.0496 0.0442
14 0.407 0.222 0.0849 0.0719 0.113 0.0513 0.0448
15 0.406 0.278 0.0719 0.0086 0.0071 0.0035 0.0335
16 0.407 0.192 0.0473 0.140 0.0356 0.0124 0.0485
17 0.407 0.216 0.0610 0.141 0.0518 0.0132 0.0504
18 0.406 0.193 0.0583 0.118 0.0554 0.0110 0.0469
19 0.406 0.181 0.0422 0.0087 0.0067 0.0220 0.0317
20 0.406 0.211 0.0469 0.116 0.0464 0.0177 0.0447
Mean ± SD 0.406 ± 0.001 0.216 ± 0.041 0.0778 ± 0.0252 0.0759 ± 0.0384 0.0619 ± 0.0274 0.0207 ± 0.0143 0.0428 ± 0.0050
LLI 5 lower large intestines; ULI 5 upper large intestines; UB 5 urinary bladder.
Patients 2 and 11 were not considered because of altered liver or kidney function.
FIGURE 4. Uptake of 68Ga-HER2-Nanobody in primary breast carcinoma lesions (arrows) on
PET/CT images (top) and PET images (bottom). (A) Patient 14 showed highest tracer uptake
(SUVmean, 11.8). (B) Patient 15 showed moderate tracer uptake, which was easily discernable
from background (SUVmean, 4.9). (C) Patient 6 showed no uptake (SUVmean, 0.9), with CT showing
marker clip at tumor region.
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or no tumor uptake in most cases, potentially related to suboptimal
mass, lower immunoreactivity, or a blood half-life of the tracer that
is too long to allow adequate PET imaging with 68Ga (29). More-
over, contrary to 68Ga-HER2-Nanobody, trastuzumab-derived
tracers bind to the same epitope as the therapeutic agent, result-
ing in changes in uptake caused by differences in circulat-
ing therapeutic compound. The Affibody molecules labeled with
68Ga and 111In are also explored as tracers for HER2 imaging.
The first-in-human data were published in 2010 (21). Mean-
while, a second compound against HER2 has been tested in a
first-in-human study and showed a decrease in liver uptake (18).
In total, 10 patients have been imaged with the different com-
pounds, which have shown fast blood clearance and high poten-
tial for tumor targeting, similar to what is reported in this paper
(18,21).
This first-in-human use of radiolabeled Nanobody exemplifies the
translational potential of a variety of preclinically tested Nanobodies
raised against a multitude of targets such as macrophage mannose
receptor for assessment of the tumor microenvironment and vascular
cell adhesion molecule 1 in atherosclerosis (30,31). In combination
with improvements in radiochemical techniques for 18F-labeling that
allow distribution of tracers to multiple centers, this anti-HER2-
Nanobody could be just the start of several exciting new PET agents.
Moreover, the recent development of targeted radionuclide therapy
using 177Lu-labeled anti-HER2-Nanobody showed impressive pre-
clinical results (32). Such a theranostic approach will soon be trans-
lated into a clinical trial.
CONCLUSION
68Ga-HER2-Nanobody PET/CT is a safe procedure with a
radiation dose comparable to that of other routinely used PET
tracers. Its biodistribution is favorable, with the highest uptake
in the kidneys, liver, and intestines but very low background
levels in all other organs that typically house primary breast
carcinoma or tumor metastasis. Tracer accumulation in the me-
tastases of HER2-overexpressing patients is high, compared
with normal surrounding tissues, and warrants further assess-
ment in a phase II trial.
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